Impacting Drug Discovery Shoulder-to-Shoulder
In July 2021, MIMETAS and Roche entered a risk-sharing collaboration to develop human disease models for the characterization of novel compounds in Inflammatory Bowel Disease (IBD) and Hepatitis B virus infections (HBV). Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche. You can find the original press release here. We are delighted to share that the partnership is going well and recently achieved important milestones in the project.
Astellas Pharma Inc. Partnership
In March 2023, MIMETAS and Astellas Pharma Inc. entersed into a strategic partnership. The partnership, which was then expanded in June 2023 to include automation and support, comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies. Under this collaboration, Astellas will receive access to MIMETAS immune oncological disease assays. MIMETAS will be eligible for upfront and milestone payments.
Learn more about Drug Discovery